MIM
XBIT icon

MetLife Investment Management’s XBiotech XBIT Stock Holding History

MetLife Investment Management’s Portfolio XBIT Stock Details XBIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-12,157
Closed -$94K – 2864
2024
Q3 		$94K Buy
+12,157
New +$79.9K ﹤0.01% 2650
2021
Q4 		– Sell
-5,892
Closed -$76.3K – 2556
2021
Q3 		$76.3K Buy
+5,892
New +$93.9K ﹤0.01% 2506
2020
Q4 		– Sell
-6,623
Closed -$126K – 2318
2020
Q3 		$126K Hold
6,623
– – ﹤0.01% 2105
2020
Q2 		$90.8K Buy
+6,623
New +$93.1K ﹤0.01% 2278
2020
Q1 		– Sell
-9,308
Closed -$174K – 2297
2019
Q4 		$174K Buy
+9,308
New +$120K ﹤0.01% 2050

Other funds holding XBIT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

MetLife Investment Management's XBIT Position: Q4 2024 in Review

MetLife Investment Management sold out of XBiotech (XBIT) in Q4 2024, closing a stake of 12,157 shares — an estimated $94K sold.

MetLife Investment Management first reported a position in XBIT in Q4 2019 and held it in 5 quarters. The position peaked at $174K in Q4 2019. 53 funds tracked by Wall St. Rank hold XBIT as of Q4 2024.

  • MetLife Investment Management reported no remaining XBiotech position as of Q4 2024 after selling out during the quarter.
  • MetLife Investment Management sold 12,157 XBiotech shares in Q4 2024, an estimated $94K.
  • MetLife Investment Management first reported a position in XBiotech in Q4 2019 and held it in 5 quarters.
  • MetLife Investment Management's XBiotech position peaked at $174K in Q4 2019.
  • 53 funds tracked by Wall St. Rank held XBiotech as of Q4 2024.

Based on MetLife Investment Management's 13F filing for Q4 2024, filed 13 Feb 2025.